This inventor holds 4 USPTO granted patents and 6 published patent applications and 5 EPO patents. Top assignees: Hoffmann-La Roche Inc., Genentech, Inc.. Active years: 2010-2015.
Company Filing History:
4 out of 5,011 
2 out of 3,288 
Years Active: 2010-2015
Title: Innovations of Joachim Moecks in Cancer Treatment
Introduction
Joachim Moecks is a notable inventor based in Mannheim, Germany. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 4 patents, his work focuses on improving patient outcomes in oncology.
Latest Patents
One of his latest patents involves predicting the response to a HER inhibitor. This application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. It also highlights the use of a high HER2:HER3 ratio as a selection criterion for treating cancer patients, including those with ovarian cancer, with a HER inhibitor. Additionally, the application discusses the use of high HER3 as a selection criterion for treating cancer patients with a chemotherapeutic agent, such as gemcitabine.
Career Highlights
Throughout his career, Joachim Moecks has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and Genentech, Inc. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.
Collaborations
Some of his notable coworkers include Andreas Strauss and Lukas C Amler. Their collaboration has likely played a role in advancing the research and development of cancer treatment options.
Conclusion
Joachim Moecks is a distinguished inventor whose work in cancer treatment has the potential to significantly impact patient care. His innovative patents and collaborations with leading companies and professionals in the field underscore his commitment to advancing medical science.